Your browser doesn't support javascript.
loading
Structure activity relationship of N-1 substituted 1,5-naphthyrid-2-one analogs of oxabicyclooctane-linked novel bacterial topoisomerase inhibitors as broad-spectrum antibacterial agents (Part-9).
Singh, Sheo B; Tan, Christopher M; Kaelin, David; Meinke, Peter T; Miesel, Lynn; Olsen, David B; Fukuda, Hideyuki; Kishii, Ryuta; Takei, Masaya; Ohata, Kohei; Takeuchi, Tomoko; Shibue, Taku; Takano, Hisashi; Nishimura, Akinori; Fukuda, Yasumichi.
Afiliação
  • Singh SB; Merck & Co., Inc., Kenilworth, NJ 07033, USA. Electronic address: sbsingh101@gmail.com.
  • Tan CM; Merck & Co., Inc., Kenilworth, NJ 07033, USA.
  • Kaelin D; Merck & Co., Inc., Kenilworth, NJ 07033, USA.
  • Meinke PT; Merck & Co., Inc., Kenilworth, NJ 07033, USA.
  • Miesel L; Merck & Co., Inc., Kenilworth, NJ 07033, USA.
  • Olsen DB; Merck & Co., Inc., West Point, PA 19486, USA.
  • Fukuda H; Kyorin Pharmaceutical Co., Ltd., 1848 Nogi, Nogi-machi, Shimotsuga-gun, Tochigi 329-0114, Japan.
  • Kishii R; Kyorin Pharmaceutical Co., Ltd., 1848 Nogi, Nogi-machi, Shimotsuga-gun, Tochigi 329-0114, Japan.
  • Takei M; Kyorin Pharmaceutical Co., Ltd., 1848 Nogi, Nogi-machi, Shimotsuga-gun, Tochigi 329-0114, Japan.
  • Ohata K; Kyorin Pharmaceutical Co., Ltd., 1848 Nogi, Nogi-machi, Shimotsuga-gun, Tochigi 329-0114, Japan.
  • Takeuchi T; Kyorin Pharmaceutical Co., Ltd., 1848 Nogi, Nogi-machi, Shimotsuga-gun, Tochigi 329-0114, Japan.
  • Shibue T; Kyorin Pharmaceutical Co., Ltd., 1848 Nogi, Nogi-machi, Shimotsuga-gun, Tochigi 329-0114, Japan.
  • Takano H; Kyorin Pharmaceutical Co., Ltd., 1848 Nogi, Nogi-machi, Shimotsuga-gun, Tochigi 329-0114, Japan.
  • Nishimura A; Kyorin Pharmaceutical Co., Ltd., 1848 Nogi, Nogi-machi, Shimotsuga-gun, Tochigi 329-0114, Japan.
  • Fukuda Y; Kyorin Pharmaceutical Co., Ltd., 1848 Nogi, Nogi-machi, Shimotsuga-gun, Tochigi 329-0114, Japan. Electronic address: yasumichi.fukuda@gmail.com.
Bioorg Med Chem Lett ; 75: 128808, 2022 11 01.
Article em En | MEDLINE | ID: mdl-35609741
ABSTRACT
Novel bacterial topoisomerase inhibitors (NBTIs) are the newest members of gyrase inhibitor broad-spectrum antibacterial agents, represented by the most advanced member, gepotidacin, a 4-amino-piperidine linked NBTI, which is undergoing phase III clinical trials for treatment of urinary tract infections (UTI). We have extensively reported studies on oxabicyclooctane linked NBTIs, including AM-8722. The present study summarizes structure activity relationship (SAR) of AM-8722 leading to identification of 7-fluoro-1-cyanomethyl-1,5-naphthyridin-2-one based NBTI (16, AM-8888) with improved potency and spectrum (MIC values of 0.016-4 µg/mL), with Pseudomonas aeruginosa being the least sensitive strain (MIC 4 µg/mL).
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Inibidores da Topoisomerase / Antibacterianos Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Inibidores da Topoisomerase / Antibacterianos Idioma: En Ano de publicação: 2022 Tipo de documento: Article